Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
نویسندگان
چکیده
منابع مشابه
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
BACKGROUND The advent of oral disease-modifying therapies fundamentally changed the treatment of multiple sclerosis. Nevertheless, impressions of their relative efficacy and tolerability are primarily founded on expert opinion. OBJECTIVE The purpose of this study was to determine whether oral disease-modifying therapies were better tolerated and/or more effective for controlling multiple scle...
متن کاملOral Disease-Modifying Therapies for Multiple Sclerosis
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely applied, remain a major concern in terms of therapeutic adherence and efficacy. New oral drugs recently approved for MS treatment represent significant advances in therapy. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. However, these drug...
متن کاملNew oral disease-modifying therapies for multiple sclerosis
Several promising, oral disease-modifying therapies for multiple sclerosis are currently being evaluated in clinical trials. The arrival of effective oral agents for multiple sclerosis will be a major advance in the global effort to alter the natural history of this chronic disease.
متن کاملAdherence to Glatiramer Acetate 40 Mg Versus Oral Disease-Modifying Therapies for Multiple Sclerosis.
GA 40 mg TIW cohort: patients with GA 40 mg on their index dates or who switched to GA 40 mg during post-index and had ≥90 days of post-index after switch; for switchers, the date of the switch to GA 40 mg became the new index date n=232 Oral DMT cohort: patients whose index DMTs were ngolimod, teri unomide, or dimethyl fumarate and who did not switch to GA 40 mg TIW during post-index n=1,547 F...
متن کاملMultiple sclerosis and disease-modifying therapies.
Mia T. Minen, MD Steven Karceski, MD Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (DMTs) have been developed. These therapies are designed to decrease the number of MS attacks, and to slow the progression of the disease. They have become a standard part of the current treatment for MS. There are different classes of the currently available DM...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal - Experimental, Translational and Clinical
سال: 2016
ISSN: 2055-2173,2055-2173
DOI: 10.1177/2055217316677868